Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDA001 in active rheumatoid arthritis
NCT01261403Phase 2Terminated
- Sponsor
- Celularity Inc.
- Start
- Dec 2010
- Primary completion
- Feb 2012
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PDA001 in rheumatoid arthritis (RA) (3 arms), sponsored by Celularity Inc. Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Dec 2010; status: terminated.
02
Drugs
PDA001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01261403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01261403.